NO922621L - Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav - Google Patents

Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav

Info

Publication number
NO922621L
NO922621L NO92922621A NO922621A NO922621L NO 922621 L NO922621 L NO 922621L NO 92922621 A NO92922621 A NO 92922621A NO 922621 A NO922621 A NO 922621A NO 922621 L NO922621 L NO 922621L
Authority
NO
Norway
Prior art keywords
antigen
treatment
applications
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO92922621A
Other languages
English (en)
Norwegian (no)
Other versions
NO922621D0 (no
Inventor
Jean-Marie Saint-Remy
Philippe Lebrun
Serge Lebeque
Pierre Lucien Masson
Marc Jacquemin
Original Assignee
Int Inst Cellular Molecul Path
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cellular Molecul Path filed Critical Int Inst Cellular Molecul Path
Publication of NO922621D0 publication Critical patent/NO922621D0/no
Publication of NO922621L publication Critical patent/NO922621L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO92922621A 1990-01-03 1992-07-02 Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav NO922621L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46051490A 1990-01-03 1990-01-03
PCT/BE1990/000074 WO1991009619A1 (en) 1990-01-03 1990-12-31 Pharmaceutical compositions containing antigen-antibody complexes and uses therefor

Publications (2)

Publication Number Publication Date
NO922621D0 NO922621D0 (no) 1992-07-02
NO922621L true NO922621L (no) 1992-09-02

Family

ID=23829022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922621A NO922621L (no) 1990-01-03 1992-07-02 Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav

Country Status (15)

Country Link
US (1) US7122380B1 (de)
EP (1) EP0508993B1 (de)
JP (1) JPH03227942A (de)
AT (1) ATE103495T1 (de)
AU (1) AU644400B2 (de)
CA (1) CA2015515C (de)
DE (1) DE69007799T2 (de)
DK (1) DK0508993T3 (de)
ES (1) ES2054484T3 (de)
HU (1) HUT62486A (de)
IE (1) IE65399B1 (de)
NO (1) NO922621L (de)
PL (1) PL288597A1 (de)
PT (1) PT96409A (de)
WO (1) WO1991009619A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095956T3 (es) * 1990-09-28 1997-03-01 British Tech Group Conjugados antigeno-anticuerpo.
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
NZ263102A (en) * 1993-03-19 1997-05-26 Immunex Corp Pharmaceutical compositions comprising a ligand protein such as interleukin-4 and a soluble receptor protein that binds thereto
FR2728264B1 (fr) * 1994-12-16 1997-01-31 Rhone Poulenc Rorer Sa Purification d'adn par formation de triple helice avec un oligonucleotide immobilise
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
AU1267501A (en) * 1999-09-07 2001-04-10 Bioserv Ag Novel autogenous vaccines used to obtain an immune tolerance
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
CN1863555A (zh) 2003-08-15 2006-11-15 卡尔加里大学理事会 操作哺乳动物中抗原特异性抗体的水平的组合物和方法
AU2011218660B2 (en) * 2003-08-15 2011-12-15 The Governors Of The University Of Calgary Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
EP1875246B1 (de) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnoseverfahren zum nachweis von krebs durch messen der menge eines cytokinähnlichen il-6
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
WO2017218677A2 (en) * 2016-06-14 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis
GB201802338D0 (en) 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140679A (en) 1976-10-12 1979-02-20 Research Corporation Antigen-protein complex for blocking allergic reactions
US4234569A (en) 1978-10-04 1980-11-18 The Johns Hopkins University Production of aldehyde-treated allergen-containing substances
DE2846412A1 (de) 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4521405A (en) 1982-05-17 1985-06-04 John McMichael Methods and materials for treatment of disease states involving immunological factors
US4545986A (en) 1982-06-22 1985-10-08 Research Corporation Timothy grass antigen specific anti-idiotypic antibodies
US4564600A (en) 1982-10-26 1986-01-14 Majid Ali Allergens and antibodies from allergen extracts and pooled serum
US4702907A (en) 1983-08-09 1987-10-27 Cornell Research Foundation, Inc. Process for inducing selective immunosuppression of antibodies
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4714759A (en) 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
GB8608068D0 (en) 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
GB8610983D0 (en) 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
DE68925899T2 (de) * 1988-04-04 1996-10-02 Byron E Anderson Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen

Also Published As

Publication number Publication date
DE69007799T2 (de) 1994-10-20
AU644400B2 (en) 1993-12-09
EP0508993A1 (de) 1992-10-21
ATE103495T1 (de) 1994-04-15
PL288597A1 (en) 1991-08-12
WO1991009619A1 (en) 1991-07-11
PT96409A (pt) 1991-10-15
HU9202214D0 (en) 1992-10-28
NO922621D0 (no) 1992-07-02
CA2015515C (en) 1999-12-07
AU6962691A (en) 1991-07-24
IE65399B1 (en) 1995-10-18
DK0508993T3 (da) 1994-05-09
IE904693A1 (en) 1991-07-17
CA2015515A1 (en) 1991-07-03
JPH03227942A (ja) 1991-10-08
DE69007799D1 (de) 1994-05-05
ES2054484T3 (es) 1994-08-01
US7122380B1 (en) 2006-10-17
HUT62486A (en) 1993-05-28
EP0508993B1 (de) 1994-03-30

Similar Documents

Publication Publication Date Title
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
MY111682A (en) Altered antibodies and their preparations.
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
IL108501A0 (en) Novel antibodies and pharmaceutical compositions containing them
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
FR2516794B1 (fr) Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
EP0735893A4 (de) Veränderung der immunantwort durch verwendung von pan dr-bindeproteinen
DK0805628T3 (da) Receptor specifik transepitheltransport af immunogener
IL89823A0 (en) Antibody hetero conjugates and pharmaceutical compositions containing them
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
CA2055615A1 (en) Monoclonal antibodies for inducing tolerance
PT840618E (pt) Inducao de tolerancia imunologica atraves de anticorpos anti-cd4 nao-depletores
EP0817650A4 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
WIGZELL Cellular immunosorbents
Houba et al. Soluble serum antigens of P. falciparum in Nigerians
ATE338819T1 (de) Antigenes protein aus malassezia
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE184315T1 (de) Neuartiges endothelzell-molekül, das die bindung von lymphozyten im menschen vermittelt
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물